Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6533872 | 0.91 | MAPK14 (0.44) | MAPK14MAPK11 | |
| SCHEMBL4377468 | 0.86 | MAPK14 (0.43) | MAPK14MAPK11ARMAOB | |
| SCHEMBL6471580 | 0.85 | MAPK14 (0.45) | MAPK14MAOB | |
| SCHEMBL6471516 | 0.85 | MAPK14 (0.51) | MAPK14MAOB | |
| SCHEMBL6471919 | 0.84 | MAPK14 (0.40) | MAPK14MAOB | |
| SCHEMBL6472203 | 0.83 | MAPK14 (0.57) | MAPK14MAOB | |
| SCHEMBL6471631 | 0.82 | MAPK14 (0.59) | MAPK14MAPK11 | |
| Hydrochloric Acid SCHEMBL6473516 | 0.81 | MAPK14 (0.39) | MAPK14MAOB | |
| SCHEMBL6472893 | 0.80 | MAPK14 (0.51) | MAPK14MAPK11 | |
| Hydrochloric Acid SCHEMBL6470993 | 0.80 | MAPK14 (0.44) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |